Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAC1 | P63000 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.53 |
| ▸ | RAD52 | P43351 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15087053 | 1.00 | RAC1 (1.00) | RAC1KMT2AMEN1NPY5RRAD52 | |
| SCHEMBL29558403 | 1.00 | RAC1 (1.00) | RAC1KMT2AMEN1NPY5RRAD52 | |
| SCHEMBL29920432 | 0.88 | RAC1 (0.79) | RAC1KMT2AMEN1NPY5RRAD52 | |
| SCHEMBL20966313 | 0.88 | RAC1 (0.79) | RAC1KMT2AMEN1NPY5RRAD52 | |
| SCHEMBL20966317 | 0.83 | RAC1 (0.71) | RAC1KMT2AMEN1NPY5RL3MBTL1 | |
| SCHEMBL29920372 | 0.83 | RAC1 (0.71) | RAC1KMT2AMEN1NPY5RL3MBTL1 | |
| SCHEMBL20945473 | 0.82 | RAC1 (0.69) | RAC1KMT2AMEN1NPY5RL3MBTL1 | |
| SCHEMBL20966330 | 0.80 | RAC1 (0.67) | RAC1KMT2AMEN1NPY5RL3MBTL1 | |
| SCHEMBL20966319 | 0.79 | RAC1 (0.65) | RAC1NPY5RRAD52L3MBTL1MAPT | |
| SCHEMBL29920699 | 0.79 | RAC1 (0.65) | RAC1NPY5RRAD52L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117618439-B | Method for inhibiting porcine epidemic diarrhea virus in vitro infection by EHop-016 and application thereof | HENAN UNIVERSITY OF ANIMAL HUSBANDRY AND ECONOMY (CN) | 2026-05-26 | — | — | CN | claimed |
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | FRED HUTCHINSON CANCER CENTER (US) | 2026-03-10 | — | — | US | claimed |
| CN-119080753-A | HinK inhibitor and preparation method and application thereof | 国科大杭州高等研究院 | 2024-12-06 | — | — | CN | claimed |
| WO-2024130030-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES THROUGH GLIAL PRUNING REGULATION | FRED HUTCHINSON CANCER CENTER (US) | 2024-06-20 | — | — | WO | claimed |
| CN-117618439-A | Method for inhibiting porcine epidemic diarrhea virus in-vitro infection by EHop-016 and application thereof | 河南牧业经济学院 | 2024-03-01 | — | — | CN | claimed |
| CN-117295522-A | Compositions and methods for megalin inhibitors and photodynamic therapy for the treatment of cancer | 香港大学 | 2023-12-26 | — | — | CN | claimed |
| EP-4240339-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | Fred Hutchinson Cancer Center (US) | 2023-09-13 | — | — | EP | claimed |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER CENTER (US) | 2023-08-24 | — | — | US | claimed |
| US-20230190736-A1 | SMALL MOLECULE THERAPEUTICS FOR THE TREATMENT OF VIRAL INFECTIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | claimed |
| CN-114225040-B | Drug for reversing drug resistance of head and neck squamous carcinoma to cetuximab and screening method thereof | 上海交通大学医学院附属第九人民医院 | 2023-05-26 | — | — | CN | claimed |
| WO-2022237864-A1 | COMPOSITIONS AND METHODS OF MACROPINOCYTOSIS INHIBITORS AND PHOTODYNAMIC THERAPY TO TREAT CANCERS | THE UNIVERSITY OF HONG KONG (CN) | 2022-11-17 | — | — | WO | claimed |
| US-20220280525-A1 | RAC INHIBITION AS A NOVEL THERAPEUTIC STRATEGY FOR EGFR/HER2 TARGETED THERAPY RESISTANT BREAST CANCER | UNITED STATES GOVERNMENT | 2022-09-08 | — | — | US | claimed |
| WO-2022098776-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-12 | — | — | WO | claimed |
| CN-114225040-A | Drug for reversing drug resistance of head and neck squamous cell carcinoma to cetuximab and screening method thereof | 上海交通大学医学院附属第九人民医院 | 2022-03-25 | — | — | CN | claimed |
| CN-117618439-B | Method for inhibiting porcine epidemic diarrhea virus in vitro infection by EHop-016 and application thereof | HENAN UNIVERSITY OF ANIMAL HUSBANDRY AND ECONOMY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117618439-B | Method for inhibiting porcine epidemic diarrhea virus in vitro infection by EHop-016 and application thereof | HENAN UNIVERSITY OF ANIMAL HUSBANDRY AND ECONOMY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-117618439-B | Method for inhibiting porcine epidemic diarrhea virus in vitro infection by EHop-016 and application thereof | HENAN UNIVERSITY OF ANIMAL HUSBANDRY AND ECONOMY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-114225040-A | Drug for reversing drug resistance of head and neck squamous cell carcinoma to cetuximab and screening method thereof | 上海交通大学医学院附属第九人民医院 | 2022-03-25 | — | — | CN | disclosed |
| CN-114225040-A | Drug for reversing drug resistance of head and neck squamous cell carcinoma to cetuximab and screening method thereof | 上海交通大学医学院附属第九人民医院 | 2022-03-25 | — | — | CN | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569494-B2 | Compositions and methods to promote thymic regeneration | CDC42, BMP4, TPMT | RAC1 105/4885KMT2A 3297/4885MEN1 1138/4885 |
| US-20230263800-A1 | COMPOSITIONS AND METHODS TO PROMOTE THYMIC FUNCTION | BMP4, P2RY2, GPR39 | RAC1 1769/4885KMT2A 4678/4885MEN1 2303/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | RAC1 4395/4885KMT2A 1178/4885MEN1 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.